Atlas Trials

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

Clinical trial NCT03369002 · COMPLETED

Trial details

NCT number
NCT03369002
Sponsor
Gilead Sciences
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2017-11-27
Primary completion
2018-05-15
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.